Clozel’s Acte­lion R&D spin­out gets a name; GSK’s new CEO won’t make as much as her pre­de­ces­sor

→ Jean-Paul Clozel has a name for his biotech spin­out. Once J&J’s $30 bil­lion deal to ac­quire Acte­lion goes through, the R&D side of the busi­ness will launch un­der the name Idor­sia. When the deal was orig­i­nal­ly an­nounced, Clozel had pen­cilled in New­Co for his next ven­ture.

→ Au­rinia $AUPH took ad­van­tage of a ris­ing share price to round up $150 mil­lion in a new of­fer­ing. But the stock took a beat­ing Tues­day af­ter the biotech de­cid­ed to of­fer the shares at a deep dis­count.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.